vs
null（EDIT）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是null的1.2倍（$30.3M vs $24.7M），null净利率更高（-22.7% vs -221.3%，领先198.6%），REGENXBIO Inc.同比增速更快（43.0% vs -19.2%），null自由现金流更多（$-36.4M vs $-52.8M），过去两年null的营收复合增速更高（366.9% vs 39.4%）
Editas Medicine是一家处于临床阶段的生物技术企业，总部位于马萨诸塞州剑桥市，在科罗拉多州博尔德市也设有研发场地，目前公司依托CRISPR基因编辑技术，开发针对罕见疾病的治疗方案。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
EDIT vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.2倍
$24.7M
营收增速更快
RGNX
高出62.2%
-19.2%
净利率更高
EDIT
高出198.6%
-221.3%
自由现金流更多
EDIT
多$16.4M
$-52.8M
两年增速更快
EDIT
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $24.7M | $30.3M |
| 净利润 | $-5.6M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -31.3% | -190.0% |
| 净利率 | -22.7% | -221.3% |
| 营收同比 | -19.2% | 43.0% |
| 净利润同比 | 87.6% | -31.2% |
| 每股收益（稀释后） | $0.03 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EDITRGNX
| Q4 25 | $24.7M | $30.3M | ||
| Q3 25 | $7.5M | $29.7M | ||
| Q2 25 | $3.6M | $21.4M | ||
| Q1 25 | $4.7M | $89.0M | ||
| Q4 24 | $30.6M | $21.2M | ||
| Q3 24 | $61.0K | $24.2M | ||
| Q2 24 | $513.0K | $22.3M | ||
| Q1 24 | $1.1M | $15.6M |
净利润EDITRGNX
| Q4 25 | $-5.6M | $-67.1M | ||
| Q3 25 | $-25.1M | $-61.9M | ||
| Q2 25 | $-53.2M | $-70.9M | ||
| Q1 25 | $-76.1M | $6.1M | ||
| Q4 24 | $-45.4M | $-51.2M | ||
| Q3 24 | $-62.1M | $-59.6M | ||
| Q2 24 | $-67.6M | $-53.0M | ||
| Q1 24 | $-62.0M | $-63.3M |
毛利率EDITRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率EDITRGNX
| Q4 25 | -31.3% | -190.0% | ||
| Q3 25 | -325.4% | -176.3% | ||
| Q2 25 | -1440.6% | -296.3% | ||
| Q1 25 | -1635.1% | 13.6% | ||
| Q4 24 | -152.2% | -242.1% | ||
| Q3 24 | -107649.2% | -256.6% | ||
| Q2 24 | -14016.2% | -251.3% | ||
| Q1 24 | -5902.3% | -408.8% |
净利率EDITRGNX
| Q4 25 | -22.7% | -221.3% | ||
| Q3 25 | -333.0% | -208.3% | ||
| Q2 25 | -1487.8% | -331.8% | ||
| Q1 25 | -1633.5% | 6.8% | ||
| Q4 24 | -148.3% | -241.3% | ||
| Q3 24 | -101870.5% | -246.3% | ||
| Q2 24 | -13178.8% | -237.7% | ||
| Q1 24 | -5458.1% | -405.4% |
每股收益（稀释后）EDITRGNX
| Q4 25 | $0.03 | $-1.30 | ||
| Q3 25 | $-0.28 | $-1.20 | ||
| Q2 25 | $-0.63 | $-1.38 | ||
| Q1 25 | $-0.92 | $0.12 | ||
| Q4 24 | $-0.55 | $-0.99 | ||
| Q3 24 | $-0.75 | $-1.17 | ||
| Q2 24 | $-0.82 | $-1.05 | ||
| Q1 24 | $-0.76 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.6M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $27.3M | $102.7M |
| 总资产 | $186.5M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EDITRGNX
| Q4 25 | $146.6M | $230.1M | ||
| Q3 25 | $165.6M | $274.2M | ||
| Q2 25 | $178.5M | $323.3M | ||
| Q1 25 | $221.0M | $267.9M | ||
| Q4 24 | $269.9M | $234.7M | ||
| Q3 24 | $265.1M | $255.5M | ||
| Q2 24 | $279.1M | $290.4M | ||
| Q1 24 | $296.2M | $338.7M |
总债务EDITRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $57.4M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EDITRGNX
| Q4 25 | $27.3M | $102.7M | ||
| Q3 25 | $13.5M | $161.5M | ||
| Q2 25 | $19.2M | $213.7M | ||
| Q1 25 | $62.4M | $274.2M | ||
| Q4 24 | $134.3M | $259.7M | ||
| Q3 24 | $175.6M | $301.4M | ||
| Q2 24 | $232.0M | $348.3M | ||
| Q1 24 | $294.4M | $390.7M |
总资产EDITRGNX
| Q4 25 | $186.5M | $453.0M | ||
| Q3 25 | $201.8M | $525.2M | ||
| Q2 25 | $210.6M | $581.0M | ||
| Q1 25 | $263.7M | $490.9M | ||
| Q4 24 | $341.6M | $466.0M | ||
| Q3 24 | $327.6M | $519.1M | ||
| Q2 24 | $384.8M | $569.4M | ||
| Q1 24 | $440.3M | $629.2M |
负债/权益比EDITRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-36.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-36.4M | $-52.8M |
| 自由现金流率自由现金流/营收 | -147.3% | -174.0% |
| 资本支出强度资本支出/营收 | 0.2% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流EDITRGNX
| Q4 25 | $-36.4M | $-52.3M | ||
| Q3 25 | $-30.8M | $-56.0M | ||
| Q2 25 | $-50.2M | $-49.3M | ||
| Q1 25 | $-47.8M | $33.6M | ||
| Q4 24 | $-50.8M | $-31.6M | ||
| Q3 24 | $-52.6M | $-40.5M | ||
| Q2 24 | $-57.1M | $-45.5M | ||
| Q1 24 | $-49.9M | $-55.5M |
自由现金流EDITRGNX
| Q4 25 | $-36.4M | $-52.8M | ||
| Q3 25 | $-31.3M | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | $-47.9M | $32.6M | ||
| Q4 24 | $-51.3M | $-32.7M | ||
| Q3 24 | $-55.5M | $-40.9M | ||
| Q2 24 | $-60.6M | $-46.0M | ||
| Q1 24 | $-51.7M | $-56.0M |
自由现金流率EDITRGNX
| Q4 25 | -147.3% | -174.0% | ||
| Q3 25 | -414.6% | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | -1028.6% | 36.6% | ||
| Q4 24 | -167.6% | -154.2% | ||
| Q3 24 | -90998.4% | -168.9% | ||
| Q2 24 | -11804.3% | -206.2% | ||
| Q1 24 | -4558.9% | -358.5% |
资本支出强度EDITRGNX
| Q4 25 | 0.2% | 1.7% | ||
| Q3 25 | 5.7% | 1.7% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 2.4% | 1.2% | ||
| Q4 24 | 1.8% | 5.1% | ||
| Q3 24 | 4788.5% | 1.3% | ||
| Q2 24 | 681.1% | 2.1% | ||
| Q1 24 | 164.8% | 3.6% |
现金转化率EDITRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EDIT
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
